Prichard David O, Bharucha Adil E
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Clinical Enteric Neuroscience Translational and Epidemiological Research Program and Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
F1000Res. 2018 Oct 15;7. doi: 10.12688/f1000research.15900.1. eCollection 2018.
Constipation, a condition characterized by heterogeneous symptoms, is common in Western society. It is associated with reduced physical health, mental health, and social functioning. Because constipation is rarely due to a life-threatening disease (for example, colon cancer), current guidelines recommend empiric therapy. Limited surveys suggest that fewer than half of treated individuals are satisfied with treatment, perhaps because the efficacy of drugs is limited, they are associated with undesirable side effects, or they may not target the underlying pathophysiology. For example, although a substantial proportion of constipated patients have a defecatory disorder that is more appropriately treated with pelvic floor biofeedback therapy than with laxatives, virtually no pharmacological trials formally assessed for anorectal dysfunction. Recent advances in investigational tools have improved our understanding of the physiology and pathophysiology of colonic and defecatory functions. In particular, colonic and anorectal high-resolution manometry are now available. High-resolution anorectal manometry, which is increasingly used in clinical practice, at least in the United States, provides a refined assessment of anorectal pressures and may uncover structural abnormalities. Advances in our understanding of colonic molecular physiology have led to the development of new therapeutic agents (such as secretagogues, pro-kinetics, inhibitors of bile acid transporters and ion exchangers). However, because clinical trials compare these newer agents with placebo, their efficacy relative to traditional laxatives is unknown. This article reviews these physiologic, diagnostic, and therapeutic advances and focuses particularly on newer therapeutic agents.
便秘是一种症状多样的疾病,在西方社会很常见。它与身体健康、心理健康和社会功能下降有关。由于便秘很少由危及生命的疾病(如结肠癌)引起,目前的指南建议进行经验性治疗。有限的调查表明,接受治疗的患者中不到一半对治疗满意,这可能是因为药物疗效有限、伴有不良副作用,或者可能未针对潜在的病理生理学。例如,虽然相当一部分便秘患者存在排便障碍,用盆底生物反馈疗法比用泻药治疗更合适,但几乎没有药物试验正式评估肛门直肠功能障碍。研究工具的最新进展增进了我们对结肠和排便功能的生理学和病理生理学的理解。特别是,现在已有结肠和肛门直肠高分辨率测压法。高分辨率肛门直肠测压法在临床实践中越来越常用,至少在美国是这样,它能对肛门直肠压力进行精细评估,并可能发现结构异常。我们对结肠分子生理学理解的进展导致了新治疗药物(如促分泌剂、促动力剂、胆汁酸转运体和离子交换抑制剂)的开发。然而,由于临床试验将这些新型药物与安慰剂进行比较,它们相对于传统泻药的疗效尚不清楚。本文综述了这些生理学、诊断和治疗方面的进展,并特别关注新型治疗药物。